Aclaris Therapeutics, Inc. (ACRS)
NASDAQ: ACRS · Real-Time Price · USD
2.460
-0.030 (-1.20%)
Nov 19, 2025, 4:00 PM EST - Market closed
Aclaris Therapeutics Revenue
Aclaris Therapeutics had revenue of $3.30M in the quarter ending September 30, 2025, a decrease of -24.09%. This brings the company's revenue in the last twelve months to $15.74M, down -41.87% year-over-year. In the year 2024, Aclaris Therapeutics had annual revenue of $18.72M, down -40.09%.
Revenue (ttm)
$15.74M
Revenue Growth
-41.87%
P/S Ratio
18.09
Revenue / Employee
$245,969
Employees
64
Market Cap
266.53M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 18.72M | -12.53M | -40.09% |
| Dec 31, 2023 | 31.25M | 1.50M | 5.03% |
| Dec 31, 2022 | 29.75M | 22.99M | 340.05% |
| Dec 31, 2021 | 6.76M | 279.00K | 4.30% |
| Dec 31, 2020 | 6.48M | 2.26M | 53.35% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
ACRS News
- 14 days ago - Aclaris Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 22 days ago - Aclaris Therapeutics to Participate in Three November Healthcare Conferences - GlobeNewsWire
- 5 weeks ago - Aclaris Therapeutics, Inc. - Special Call - Seeking Alpha
- 7 weeks ago - Aclaris Therapeutics to Host In-Person and Webcast R&D Day, “Patient Focused Innovation: Addressing Gaps in Immuno-Inflammatory Markets”, in New York on October 14, 2025 - GlobeNewsWire
- 2 months ago - Aclaris Therapeutics Announces Late-Breaking Abstract and Oral Presentation On ATI-2138 Phase 2a Results at the 2025 European Academy of Dermatology and Venereology (EADV) Congress - GlobeNewsWire
- 3 months ago - Aclaris Therapeutics to Participate in Two September Healthcare Conferences - GlobeNewsWire
- 3 months ago - Aclaris Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 4 months ago - Aclaris Therapeutics Announces Positive Top-Line Results from Open-Label Phase 2a Trial of ATI-2138, a Potent and Selective Investigational Inhibitor of ITK and JAK3; Trial Achieves Primary and Key Secondary Endpoints - GlobeNewsWire